421 related articles for article (PubMed ID: 15589595)
1. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract][Full Text] [Related]
2. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
3. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract][Full Text] [Related]
4. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
[TBL] [Abstract][Full Text] [Related]
5. c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment.
Raspollini MR; Amunni G; Villanucci A; Pinzani P; Simi L; Paglierani M; Taddei GL
Clin Cancer Res; 2004 May; 10(10):3500-3. PubMed ID: 15161707
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 expression in postmastectomy chest wall relapse.
Kim JH; Bossuyt V; Ponn T; Lannin D; Haffty BG
Clin Cancer Res; 2005 Jul; 11(14):5199-205. PubMed ID: 16033837
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy.
Kim YB; Kim GE; Cho NH; Pyo HR; Shim SJ; Chang SK; Park HC; Suh CO; Park TK; Kim BS
Cancer; 2002 Aug; 95(3):531-9. PubMed ID: 12209745
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-kit in uterine carcinosarcoma.
Menczer J; Kravtsov V; Levy T; Berger E; Glezerman M; Avinoach I
Gynecol Oncol; 2005 Jan; 96(1):210-5. PubMed ID: 15589603
[TBL] [Abstract][Full Text] [Related]
9. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
11. Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Massard C; Voigt JJ; Laplanche A; Culine S; Lortholary A; Bugat R; Theodore C; Priou F; Kaminsky MC; Lesimple T; Pivot X; Coudert B; Douillard JY; Merrouche Y; Fizazi K
Br J Cancer; 2007 Oct; 97(7):857-61. PubMed ID: 17876336
[TBL] [Abstract][Full Text] [Related]
12. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
13. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.
Perrone G; Santini D; Vincenzi B; Zagami M; La Cesa A; Bianchi A; Altomare V; Primavera A; Battista C; Vetrani A; Tonini G; Rabitti C
Histopathology; 2005 May; 46(5):561-8. PubMed ID: 15842638
[TBL] [Abstract][Full Text] [Related]
14. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
15. Differential cyclooxygenase-2 expression in squamous cell carcinoma and adenocarcinoma of the uterine cervix.
Kim YB; Kim GE; Pyo HR; Cho NH; Keum KC; Lee CG; Seong J; Suh CO; Park TK
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):822-9. PubMed ID: 15465199
[TBL] [Abstract][Full Text] [Related]
16. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications.
Micke P; Basrai M; Faldum A; Bittinger F; Rönnstrand L; Blaukat A; Beeh KM; Oesch F; Fischer B; Buhl R; Hengstler JG
Clin Cancer Res; 2003 Jan; 9(1):188-94. PubMed ID: 12538468
[TBL] [Abstract][Full Text] [Related]
17. Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer.
Palmu S; Söderström KO; Quazi K; Isola J; Salminen E
Anticancer Res; 2002; 22(1A):411-4. PubMed ID: 12017324
[TBL] [Abstract][Full Text] [Related]
18. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
Riener EK; Arnold N; Kommoss F; Lauinger S; Pfisterer J
Gynecol Oncol; 2004 Oct; 95(1):89-94. PubMed ID: 15385115
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
Half E; Tang XM; Gwyn K; Sahin A; Wathen K; Sinicrope FA
Cancer Res; 2002 Mar; 62(6):1676-81. PubMed ID: 11912139
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 and c-erbB-2 expression in uterine cervical neoplasm assessed using tissue microarrays.
Kim JY; Lim SJ; Park K; Lee CM; Kim J
Gynecol Oncol; 2005 May; 97(2):337-41. PubMed ID: 15863127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
